Worldwide revenue increased 15% to $55.7 million in the third quarter.
The iFuse Granite Onyx clearance expands the addressable market to $5 billion.
Active physicians grew 16% year over year to 1,770 doctors.
On its third-quarter 2026 earnings call, held on Nov. 2, 2026, SI-BONE (NASDAQ:SIBN) announced a 15% increase in worldwide revenue to $55.7 million, driven by expanding adoption of its surgical implants. The medical device maker is extending its anatomical fixation products into wider spinal applications, positioning itself to capture a larger share of complex surgeries.
Three things management said stand out.
Management launched iFuse Granite Onyx, a medical device designed to fix spinal fusion failures, following clearance from the Food and Drug Administration (FDA). This product extends the company's addressable market by targeting procedures that suffer from high failure rates.
The addition of Onyx increases our estimated total addressable market to over 650,000 procedures, representing an annual total market opportunity of approximately $5 billion.
-- Laura Francis, Chief Executive Officer
Updated Medicare severity diagnosis-related groups (DRGs), which define fixed payment rates for hospital stays, took effect in October to cover complex spinal surgeries. Higher reimbursement reduces financial hurdles for surgical centers, paving the way for wider platform adoption.
Depending on patient diagnosis and severity, the increase in the average hospital payment could be up to $50,000 per qualifying procedure.
-- Laura Francis, Chief Executive Officer
The commercial network expanded to 1,770 active doctors performing procedures, representing a 16% increase year over year. A broader physician footprint gives the company immediate access to cross-sell new device lines without expanding overhead at the same rate.
When Granite launched in 2022, we had over 700 active physicians... Today, we have approximately 1,770 active physicians and over 300 agents.
-- Laura Francis, Chief Executive Officer
Procedure demand is accelerating across surgical centers, and executive leadership is displaying clear momentum.
We delivered a solid third quarter with accelerating procedure demand, broader physician adoption and improving financial performance.
-- Laura Francis, Chief Executive Officer
The company relies on custom implant engineering and established training networks to shield its platform from rivals. Management is keeping close watch on pricing discipline and sales productivity as product launches roll out.
Looking ahead, we're very confident in our ability to accelerate growth, improve profitability and help more patients achieve better outcomes.
-- Laura Francis, Chief Executive Officer
Before you buy stock in SI-Bone, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SI-Bone wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.